Novartis AG ADR (NVS)vsSTAAR Surgical Company (STAA)
NVS
Novartis AG ADR
$142.71
+0.60%
HEALTHCARE · Cap: $271.25B
STAA
STAAR Surgical Company
$19.08
-3.64%
HEALTHCARE · Cap: $1.18B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 16595% more annual revenue ($56.69B vs $339.59M). NVS leads profitability with a 22.5% profit margin vs 1.1%. STAA appears more attractively valued with a PEG of 0.76. STAA earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
STAA
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-53.7%
Fair Value
$93.40
Current Price
$142.71
$49.31 premium
Margin of Safety
+52.0%
Fair Value
$35.94
Current Price
$19.08
$16.86 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Revenue surging 111.0% year-over-year
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Grey zone — moderate risk
Smaller company, higher risk/reward
1.1% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : STAA
The strongest argument for STAA centers on Revenue Growth, Debt/Equity, PEG Ratio. Revenue growth of 111.0% demonstrates continued momentum. PEG of 0.76 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : STAA
The primary concerns for STAA are Altman Z-Score, Market Cap, Profit Margin. A P/E of 295.3x leaves little room for execution misses. Thin 1.1% margins leave little buffer for downturns.
Key Dynamics to Monitor
NVS profiles as a value stock while STAA is a hypergrowth play — different risk/reward profiles.
STAA carries more volatility with a beta of 1.22 — expect wider price swings.
STAA is growing revenue faster at 111.0% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 51/100), backed by strong 22.5% margins. STAA offers better value entry with a 52.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →STAAR Surgical Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
STAAR Surgical Company designs, develops, manufactures, markets and sells implantable eye lenses and supplemental delivery systems for placing the lenses in the eye. The company is headquartered in Lake Forest, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?